Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Study Suggests EpiPens Still Viable After Expiration Date

By Ryan Bushey | May 9, 2017

The life-saving allergy treatment EpiPen may still be potent for up to four years after their printed expiration dates.

The manufacturer of EpiPen, Mylan, advises patients to replace the devices annually, according to Reuters.

However, a research team led by Lee Cantrell, a professor of medicine and pharmacy at the University of California, San Diego performed a study to gauge the potency of these injectors after this period since Cantrell was concerned that the surging prices for this treatment could make it difficult for families to purchase yearly replacements.=

Mylan came under fire last year for increasing the price of these injectors by nearly 450 percent over the course of 10 years.

Over the course of two weeks, patients at a community clinic in San Diego brought unused, expired EpiPens so they could be examined by the scientists.

The team evaluated 40 expired EpiPens and EpiPen juniors with the goal of testing the Epinephrine concentrations residing in these shots.

Results indicated that the injectors did lose their potency over time, but even 50 months past the expiration date the EpiPens retained 84 percent of their epinephrine concentrations—more  than enough to effectively treat patients who enter anaphylactic shock.

The lowest level of epinephrine was 81 percent in an EpiPen Jr 30 months past its expiration date.

These findings support previous research finding that epinephrine auto-injectors have a much longer shelf-life than the labels said, wrote CNN.

Ultimately, Cantrell is calling on regulators and Mylan to reconsider the life span of these products.

“Our paper is not suggesting that people take expired medication,” Cantrell told CNN. We can’t make that leap based on our data. But what we can say is that if you have nothing else, and you’re having a life-threatening reaction, certainly use the expired epinephrine.”

The study was published in the journal Annals of Internal Medicine.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
China’s biopharma sector enters ‘innovation 2.0’ era
The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE